Statement of Changes in Beneficial Ownership (4)
June 02 2020 - 6:59PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Ciaffoni Joseph |
2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC
[
COLL
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CEO |
(Last)
(First)
(Middle)
C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/1/2020 |
(Street)
STOUGHTON, MA 02072
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/1/2020 | | F | | 4672 (1) | D | $21.24 | 204515 | D | |
Common Stock | 6/1/2020 | | M | | 64820 | A | $8.22 | 269335 | D | |
Common Stock | 6/1/2020 | | S(2) | | 70576 | D | $21.53 (3) | 198759 | D | |
Common Stock | 6/1/2020 | | S(2) | | 100 | D | $22.08 | 198659 | D | |
Common Stock | 6/2/2020 | | S(2) | | 5761 | D | $20.47 (4) | 192898 | D | |
Common Stock | 6/2/2020 | | S(2) | | 100 | D | $21.3 | 192798 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Purchase) | $8.22 | 6/1/2020 | | M | | | 64820 | (5) | 5/31/2027 | Common Stock | 64820 | $0 | 64821 | D | |
Explanation of Responses: |
(1) | Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. |
(2) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. |
(3) | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.02, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4). |
(4) | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.92, inclusive. |
(5) | 64,820 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Ciaffoni Joseph C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON, MA 02072 | X |
| President and CEO |
|
Signatures
|
/s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni | | 6/2/2020 |
**Signature of Reporting Person | Date |
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024